Skip to main content
Erschienen in: Drugs 17/2002

01.12.2002 | Adis Drug Profile

Bicalutamide

A Viewpoint by Amir V. Kaisary

verfasst von: Amir V. Kaisary

Erschienen in: Drugs | Ausgabe 17/2002

Einloggen, um Zugang zu erhalten

Excerpt

Since bicalutamide was added to the anti-androgen family of drugs, it has shown various characteristics that have established its value in the management of prostate cancer. This article presents to the reader an excellent review of its role in early-stage disease. …
Literatur
1.
Zurück zum Zitat Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 Jul 13; 360(9327): 103–6PubMedCrossRef Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 Jul 13; 360(9327): 103–6PubMedCrossRef
Metadaten
Titel
Bicalutamide
A Viewpoint by Amir V. Kaisary
verfasst von
Amir V. Kaisary
Publikationsdatum
01.12.2002
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 17/2002
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200262170-00008

Weitere Artikel der Ausgabe 17/2002

Drugs 17/2002 Zur Ausgabe

Adis New Indication Profile

Bicalutamide

Leading Article

Statins and Menopause

Current Opinion

Influenza Vaccinations

Adis New Indication Profile

Anastrozole